GlobalData on MSN1d
Boehringer and partners commence gene therapy trial for cystic fibrosis
Boehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced ...
GlobalData on MSN2d
FDA grants priority review for Boehringer’s zongertinib NDA in NSCLC
The US Food and Drug Administration (FDA) has granted priority review to Boehringer Ingelheim’s new drug application (NDA) ...
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...
Oxford Biomedica to support Boehringer Ingelheim’s LENTICLAIR 1 trial
OXB announces that its proprietary lentiviral vector manufacturing technology will be used in Boehringer Ingelheim’s newly initiated LENTICLAIR ...
pharmaphorum2d
Boehringer eyes third quarter FDA verdict for oral HER2 drug
AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has ...
Morningstar3d
Boehringer Ingelheim Pharmaceuticals, Inc. Welcomes Brian Hilberdink as President, U.S. Human Pharma
RIDGEFIELD, Conn., Feb. 20, 2025 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today the appointment of Brian Hilberdink as President, U.S ...
PharmiWeb2d
Boehringer’s zongertinib receives Priority Review…
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment of adult ...
FierceBiotech1d
Chutes & Ladders—NIH leaders join health agency exodus
The NIH has lost two distinguished leaders as mass layoffs directed by the Trump administration hit federal health agencies.
Khaleej Times on MSN4h
Look: Dubai Miracle Garden unveils new lung-shaped installation; here’s why
When you visit Dubai Miracle Garden next, you will encounter an 'impossible-to-ignore' installation with an important health ...
cambridgeindependent1d
Boehringer Ingelheim to use ExpressionEdits’ Genetix Syntax Engine for two gene therapy targets
An intron is a non-coding section of DNA or RNA within a gene that is removed during protein synthesis. ExpressionEdits is using introns – which had generally been derided as of no value – to enhance ...
Contract Pharma2d
Boehringer Ingelheim Names Brian Hilberdink as President, U.S. Human Pharma
Boehringer Ingelheim Pharmaceuticals Inc. has appointed Brian Hilberdink as President, U.S. Human Pharma.